See disease through biology.

We decode the biological signals driving disease using AI, starting with coronary artery disease.

ISO 13485

ISO 27001

The biology is already in the blood

Coronary artery disease leaves measurable traces in routine clinical chemistry. Cardio Explorer® reads those biological signals and translates them into an individualised likelihood of obstructive disease.

Individualised, sex-specific pre-test probability from routine blood chemistry
No new tests or sampling: signals extracted from data already captured
Validated against invasive coronary angiography across European cohorts

More than a decade of peer-reviewed evidence

A continuous research program: from the foundational diagnostic algorithm to independent validation across Europe and a prospective implementation study now underway.

Explore the clinical evidence

Clinical studiesFrom algorithm development through intended-use validation.

CountriesSwitzerland, Germany, and the Netherlands.

>4,500

PatientsAcross retrospective cohorts and ongoing prospective evaluation.

Making coronary artery disease visible earlier

A normal troponin and ECG rule out myocardial infarction. They do not rule out obstructive coronary artery disease. Cardio Explorer® estimates each patient's likelihood of obstructive CAD from routine clinical and laboratory data.

Hidden disease

Routine assessment can exclude an acute myocardial infarction while clinically important coronary artery disease remains undetected. In the ROMICAT II trial, around 1 in 8 chest pain patients with a normal initial troponin and ECG had significant coronary stenosis (≥50%) on CT angiography.^{1 (source 1)}

Made visible

Cardio Explorer® combines routine clinical data and standard blood tests into an individual pre-test probability of obstructive CAD.

Earlier action

A low estimate supports deferring further testing. A high estimate supports referral for CT angiography or functional testing.

Chest pain: troponin-negative ED patients (normal initial troponin and ECG): Ferencik et al., JACC Cardiovasc Imaging 2015 (ROMICAT II), n = 160, ≥50% stenosis on CCTA, doi:10.1016/j.jcmg.2015.06.016.
Atrial fibrillation: patients undergoing AF ablation work-up: Herczeg et al., Coron Artery Dis 2023, n = 2,321, ≥50% stenosis on CCTA, doi:10.1097/MCA.0000000000001201.
Heart failure: patients admitted with HFpEF: Rush et al., JAMA Cardiol 2021, n = 106; 38 of 106 enrolled (51% of those catheterised), doi:10.1001/jamacardio.2021.1825.

Built into the systems your team already uses

Cardio Explorer® runs natively inside Dedalus ORBIS, on routine data already captured — no new tests, no new documentation, no new workflow.

Using a different clinical information system? Contact our team.

Reach out

Your EMR

Outcomes that matter

Cardio Explorer® is designed to help identify patients with clinically significant coronary artery disease earlier and support more deliberate allocation of cardiovascular resources.

Identify

More actionable CAD identified

Surface patients with clinically significant coronary artery disease who may otherwise remain undiagnosed.

Prioritize

Higher-yield coronary pathways

Improve the proportion of patients progressing through advanced imaging and invasive evaluation who have actionable disease.

Optimize

Better use of scarce cardiovascular resources

Focus specialist time, imaging capacity, and cath-lab utilization where they can create the greatest clinical impact.

Built with the teams who run cardiac care

We believe Cardio Explorer®, Exploris Health's innovative cardiac test, will significantly improve care for patients with suspected coronary artery disease.

Dr. med. Thomas Helms

Chairman of the Board, German Foundation for the Chronically Ill

This is certainly an important step forward and has a big potential for the entire diagnostic process of coronary artery disease.

Prof. Hans-Peter Brunner-La Rocca

Vice Chairman, Department of Cardiology — Head, Heart Failure Clinic, Maastricht University Medical Centre

From data to diagnostic confidence. The Cardio Explorer® unlocks the full potential of available patient data to safely rule out coronary artery disease.

Michael Zellweger, MD

Professor of Cardiology — Head of Cardiac Imaging, Cardiology Department, University Hospital Basel, Switzerland